A detailed history of Bank Of America Corp transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 5,654 shares of SPRO stock, worth $5,371. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,654
Previous 5,558 1.73%
Holding current value
$5,371
Previous $7,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.19 - $1.5 $114 - $144
96 Added 1.73%
5,654 $7,000
Q2 2024

Aug 14, 2024

BUY
$1.27 - $1.8 $464 - $658
366 Added 7.05%
5,558 $7,000
Q1 2024

May 15, 2024

SELL
$1.35 - $1.79 $753 - $998
-558 Reduced 9.7%
5,192 $8,000
Q4 2023

Feb 14, 2024

SELL
$1.0 - $1.47 $7,487 - $11,005
-7,487 Reduced 56.56%
5,750 $8,000
Q2 2023

Aug 14, 2023

SELL
$1.42 - $1.95 $7,355 - $10,101
-5,180 Reduced 28.13%
13,237 $19,000
Q1 2023

May 12, 2023

BUY
$1.35 - $2.0 $14,146 - $20,958
10,479 Added 132.01%
18,417 $26,000
Q4 2022

Feb 10, 2023

SELL
$1.55 - $2.12 $2,856 - $3,907
-1,843 Reduced 18.84%
7,938 $13,000
Q3 2022

Nov 14, 2022

SELL
$0.68 - $2.2 $5,979 - $19,346
-8,794 Reduced 47.34%
9,781 $19,000
Q2 2022

Aug 12, 2022

BUY
$0.74 - $7.44 $6,486 - $65,211
8,765 Added 89.35%
18,575 $13,000
Q1 2022

May 16, 2022

SELL
$7.87 - $15.15 $250,604 - $482,421
-31,843 Reduced 76.45%
9,810 $85,000
Q4 2021

Feb 08, 2022

BUY
$13.09 - $18.77 $366,323 - $525,278
27,985 Added 204.75%
41,653 $667,000
Q3 2021

Nov 15, 2021

BUY
$13.03 - $19.51 $77,750 - $116,416
5,967 Added 77.48%
13,668 $251,000
Q2 2021

Sep 13, 2021

BUY
$12.22 - $15.79 $94,106 - $121,598
7,701 New
7,701 $107,000

Others Institutions Holding SPRO

About Spero Therapeutics, Inc.


  • Ticker SPRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,067,500
  • Market Cap $33.3M
  • Description
  • Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...
More about SPRO
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.